# GPER1 as a therapeutic target in MASLD: evidence for steatosis attenuation by agonist G1 in preclinical models

## TL;DR

This study shows that GPER1 is linked to liver fat in MASLD and that its agonist G1 can reduce steatosis in preclinical models.

## Contribution

The study provides new evidence that GPER1 agonist G1 reduces hepatic steatosis via multiple mechanisms in MASLD models.

## Key findings

- GPER1 expression is low in MASLD patients and correlates with steatosis severity.
- G1 reduces hepatocyte steatosis and lipid deposition by modulating lipid metabolism and oxidative stress.
- GIPC1 interacts with GPER1 and may play a role in its regulatory pathway.

## Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality. Premenopausal women have a lower MASLD risk than postmenopausal women. G protein-coupled estrogen receptor 1 (GPER1) exerts hepatic protective effects, and GPER1 specific agonist (G1) has shown preclinical potential in improving metabolic disorders. However, clinical studies on G1’s metabolic benefits and GPER1’s clinical relevance in human liver tissue remain unclear. This study aims to bridge basic and clinical research by validating G1’s efficacy in ameliorating MASLD-related hepatic steatosis, exploring its molecular mechanisms, and clarifying GPER1’s association with human MASLD.

We investigated the expression of GPER1 in human liver tissue and its correlation with the severity of steatosis. The function of GPER1 was validated both in vitro (using a free fatty acid-induced hepatocyte steatosis model treated with the GPER1 agonist G1 or antagonist G15) and in vivo, with assessments of lipid metabolism-related genes, reactive oxygen species, and apoptosis. GPER1-associated proteins were identified through proteomic sequencing and co-immunoprecipitation.

GPER1 is lowly expressed in MASLD patients, negatively correlating with steatosis severity. G1 upregulates GPER1, alleviates hepatocyte steatosis and lipid deposition, modulates lipid metabolism-related proteins, ameliorates hepatic steatosis, and interacts with GAIP-interacting protein C-terminal 1 (GIPC1). G15 antagonizes these beneficial effects.

Based on clinical data, this study shows that low GPER1 expression correlates closely with hepatic steatosis in MASLD. The GPER1 agonist G1 ameliorates hepatic steatosis via multiple GPER1-dependent mechanisms, including regulating lipid metabolism, suppressing oxidative stress, and reducing apoptosis. Notably, GIPC1 may be involved in the GPER1-mediated regulatory pathway, and its role in this context merits further investigation.

Created with BioGDP.com; (Jiang et al., 2025).Blank white background with no visible objects, patterns, or text. Image serves as a decorative or spacer element and conveys no informational content.

Created with BioGDP.com; (Jiang et al., 2025).